Streetbeat News

Price Targets

BCC

Truist Securities analyst Michael Roxland has maintained a 'Buy' rating on Boise Cascade (NYSE:BCC) but lowered the price target from $129 to $126.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:24 pm

ETN

Shares of Eaton Corporation (ETN) are trading higher after several firms increased their price targets on the stock. This follows the company's Q3 financial results which were released yesterday.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:22 pm

AMD

Truist Securities analyst William Stein maintains a 'Hold' rating on Advanced Micro Devices (AMD) and lowers the price target from $128 to $98.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:22 pm

IRT

JMP Securities analyst Aaron Hecht maintains a Market Outperform rating on Independence Realty Trust (NYSE:IRT) but lowers the price target from $20 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:16 pm

STVN

Jefferies has downgraded Stevanato's stock from Buy to Hold and reduced its price target from $39 to $29. This has led to a decrease in the trading price of Stevanato shares.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:13 pm

BRSP

JMP Securities analyst Chris Muller maintains a Market Outperform rating on BrightSpire Capital (NYSE:BRSP) but lowers the price target from $9.5 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:10 pm

CNTX

HC Wainwright has upgraded Context Therapeutics from Neutral to Buy and set a price target of $5. This has led to an increase in the trading of Context Therapeutics' shares.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:10 pm

SOPA

Greenridge Global analyst William Gregozeski has initiated coverage on Society Pass (NASDAQ:SOPA) with a Buy rating and a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:06 pm

NEXA

Scotiabank analyst Orest Wowkodaw has downgraded Nexa Res (NYSE:NEXA) from Sector Perform to Sector Underperform and lowered the price target from $5 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 5:04 pm

NBIX

Raymond James has maintained its Outperform rating for Neurocrine Biosciences (NASDAQ:NBIX) and increased its price target from $135.00 to $145.00. This new target price represents a potential 30.7% increase from the current share price. Neurocrine Biosciences is a pharmaceutical company with three late-stage clinical programs.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 5:00 pm